MedImmune Ventures

About The Fund

MedImmune Ventures was the corporate venture capital arm of MedImmune, serving as an investment platform that specialized in discovering, developing, and commercializing innovative biomedical and healthcare products. With its establishment in 2002 and headquarters in Gaithersburg, Maryland, United States, MedImmune Ventures played a key role in funding entrepreneurship in life sciences. Their investment focus extended to private companies engaged in the development of small and large molecules, vaccines, pharmaceutical technologies, and various platforms aimed at improving human health. They were not limited to biopharmaceuticals, as their portfolio also included investments in medical devices, diagnostics, imaging, and healthcare information technology sectors. MedImmune Ventures had a broad investment range, typically allocating anywhere from $7,000,000 to $50,602,514 in companies they believed had the potential to make significant impacts in the medical and healthcare field. As a corporate venture capital entity, they aimed to bridge the gap between scientific discovery and pharmaceutical product availability, supporting the advancement of treatments and solutions that could lead to improvements in patient outcomes. Although primarily focused on later-stage funding, their contributions were crucial in accelerating the growth and development of companies within the healthcare ecosystem. MedImmune Ventures’ initiative and funding approach highlight the importance of corporate investment in fostering innovation and technological progress in healthcare and medicine.